 Consecutive patients with stable multiple sclerosis are being recruited from the neurological services of IMSS at the hospital CMN Siglo XXI over the period of 1 year. Of those meeting inclusion criteria, 24 will be selected for the study. After signing an informed consent, they will be randomized into 12 for the intervention arm and 12 for the placebo arm. All patients will receive capsules for daily consumption according to their assignment, with no visible difference between capsules. Dosage will be 6.5-7.5 mgkg to a limit of 50 mg. These capsules will be taken for a period of 4 months. A battery of neuropsychological tests will be administered at baseline, after 4 months, and after an additional four months of follow-up to assess cognitive performance and motor function. Emotional state will be assessed with the Beck Depression Inventory at each of the three aforementioned points. 